Compare XBIT & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | III |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | 1500 |
| Industry | Pharmaceuticals and Biotechnology | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.0M | 203.8M |
| IPO Year | 2015 | 2006 |
| Metric | XBIT | III |
|---|---|---|
| Price | $2.44 | $4.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 21.3K | ★ 211.1K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.46% |
| EPS Growth | N/A | ★ 216.67 |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $192,745,000.00 |
| Revenue This Year | N/A | $3.85 |
| Revenue Next Year | N/A | $4.34 |
| P/E Ratio | ★ N/A | $82.70 |
| Revenue Growth | N/A | ★ 4.51 |
| 52 Week Low | $2.09 | $3.74 |
| 52 Week High | $3.61 | $6.45 |
| Indicator | XBIT | III |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 53.63 |
| Support Level | $2.15 | $4.12 |
| Resistance Level | $2.49 | $4.37 |
| Average True Range (ATR) | 0.06 | 0.16 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 4.17 | 64.77 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Information Services Group Inc is an AI-centered technology research and advisory firm providing digital transformation and technology advisory services that help organizations optimize performance, reduce costs, and accelerate innovation. The Company's expertise includes sourcing advisory, cloud and data analytics, managed governance and risk services, network and software advisory, technology strategy and operations design, change management, and market intelligence, serving both private- and public-sector clients globally. It operates in one segment, fact-based sourcing advisory services, and operates principally in the Americas, with generate maximum revenue in Europe and the Asia Pacific.